Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
复制标题
DOI：
10.1007/s10549-008-0128-9
复制
发表时间：
2009-05-01
影响因子：
3.8
通讯作者：
Narod, S. A.
中科院分区：
文献类型：
--
作者：
Byrski, T.;Huzarski, T.;Narod, S. A.
背景2006年12月至2007年12月期间，10例乳腺癌和乳腺癌易感基因1（BRCA 1）突变的I至III期乳腺癌患者接受了4个周期的新辅助顺铂治疗，随后进行乳房切除术和常规化疗。方法对手术切除的乳腺组织及淋巴结进行检查，以确定是否有残留病灶。结果9例（90%）患者病理完全缓解。结论含铂化疗对高比例的BRCA1相关乳腺癌患者有效。现在有必要进行临床试验，以确定这一亚组乳腺癌患者的最佳治疗方法。
Background Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant cisplatin, followed by mastectomy and conventional chemotherapy. Methods The excised breast tissue and lymph nodes were examined for the presence of residual disease. Results Pathologic complete response was observed in nine patients (90%). Conclusions Platinum-based chemotherapy appears to be effective in a high proportion of patients with BRCA1-associated breast cancers. Clinical trials are now warranted to determine the optimum treatment for this subgroup of breast cancer patients.